[Treatment of hyperkinetic heart syndrome with alinidine and propranolol].

Abstract

A hyperkinetic heart syndrome has been diagnosed in 10 patients by clinical investigation and right-heart catheterization at rest and during exercise. Subsequently, the patients received 3 X 40 mg alinidine, and 2 X 40 mg propranolol and placebo, each for 2 weeks in a double-blind crossover study. Heart rate at rest (P less than 0.05) and during exercise (P less than 0.001) decreased significantly under alinidine and propranolol to the same extent (control, 83/170; alinidine, 68/146; propranolol, 73/139; placebo, 83/162 beats per min). Lower limb flow at rest and after exercise, measured by plethysmography, as well as left-ventricular fractional shortening and mean velocity of circumferential fiber shortening, measured by echocardiography, decreased insignificantly. Sedation and a dry mouth occurred in six patients under alinidine, while fatigue and cold hands and/or feet were reported by five patients under propranolol. Thus, alinidine may be used as an alternative to beta-blocking in the treatment of the hyperkinetic heart syndrome.

• Authors: R Schräder, G Degoutrie, H Landgraf, M Kaltenbach
• Journal: Klinische Wochenschrift (Klin Wochenschr) Vol. 65 Issue 2 Pg. 69-75 (Jan 15 1987) ISSN: 0023-2173 [Print] Germany
• Vernacular Title: Behandlung des hyperkinetischen Herzsyndroms mit Alinidine und Propranolol.
• PMID: 3560788 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Cardiovascular Agents
• Propranolol
• alinidine
• Clonidine

Topics

• Adult
• Blood Pressure (drug effects)
• Cardiovascular Agents (blood, therapeutic use)
• Clonidine (analogs & derivatives, blood, therapeutic use)
• Echocardiography
• Female
• Heart Rate (drug effects)
• Humans
• Male
• Middle Aged
• Neurocirculatory Asthenia (drug therapy)
• Propranolol (blood, therapeutic use)